We and other groups have recently reported
The dependence of proviral DNA replication on host dNTP synthesis is an intrinsic property of human immunodeficiency virus type 1 . This is a consequence of the lack of HI V-1-specific enzymes (ribonucleotide reductase, nucleoside kinases, and deoxyribonucleases) for the synthesis of dNTPs (1) . The replication cycle of HIV-1, however, proceeds at an extremely high rate (-109 virions per day in a typical HIV-1-infected individual) (2, 3) and thus requires a continuous supply of dNTPs. A decrease in pools of dNTPs retards the processive action of the reverse transcriptase and, consequently, not only reduces the rate of reverse transcription but also impairs the completion of the newly synthesized DNA products, indicating that host-cell dNTP synthesis plays an essential role in HIV-1 replication (4). Furthermore, the high rate of the HIV-1 replication cycle is reflected in the rapid development of drug-resistant mutants (=104 to 105 singlepoint mutations per day), which is a major cause of the failure of current HIV-1 therapy (3) . However, HIV-1 requires host dNTPs for drug-resistant mutations to develop and host-cell proteins do not mutate as readily, even under pharmacological pressure. Thus, restriction of host dNTP synthesis may represent a strategy not only for inhibiting the rate of HIV-1 replication but also for slowing the development of drugresistant mutants. We (5) and others (6, 7) have reported that the ribonucleotide reductase inhibitor hydroxyurea increases the anti-HIV-1 activities of the 2',3'-dideoxynucleosides 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxycytidine (ddCyd), and particularly 2',3'-dideoxyinosine (ddIno) in primary cultured human peripheral blood mononuclear (PBM) cells, and the combination of hydroxyurea and ddlno is presently in early clinical trials (6) .
Since hydroxyurea is a known inhibitor of ribonucleotide reductase, inhibition of host-cell dNTP synthesis has been proposed as a possible explanation for all hydroxyureaenhanced dideoxynucleoside activities (7) . It may, however, still be premature to speculate on the nature of hydroxyurea enhancement of dideoxynucleoside activities. Host-cell dNTPs can arise via the de novo pathway involving ribonucleotide reductase or the salvage pathway using preformed deoxyribonucleosides and deoxyribonucleoside kinases. Bianchi et al. (8) initially reported murine cell studies in which hydroxyurea (0.1 mM and 3 mM) paradoxically increased dTTP pools. Whether or not low-dose hydroxyurea (-0.1 mM) can increase dTTP levels of primary cultured human PBM cells has not, however, been demonstrated. Earlier, investigators have shown (9) that for pyrimidine dideoxynucleosides (AZT and 3'-fluorothymidine), hydroxyurea can substantially increase dideoxynucleoside phosphorylation without a concomitant decrease of dNTPs (9) . This disparity indicated that hydroxyurea might enhance AZT and ddCyd activity in phytohemagglutinin (PHA)-stimulated PBM cells through a mechanism other than inhibition of pyrimidine dNTP formation. GBq) for 12 h in the presence of hydroxyurea at indicated concentrations. Intracellular 3'-azido-3'-deoxythymidine 5'-triphosphate (AZTTP), 2',3'-dideoxycytidine 5'-triphosphate (ddCTP), and 2' ,3 '-dideoxyadenosine 5 '-triphosphate (ddATP) (from ddIno treatment) were quantified by HPLC by using an ion-exchange column (Partisil 10-SAX; Whatman) as described (10) .
MATERIALS AND METHODS
Quantification of dNTP Pools. Cellular dNTP pools were quantified essentially as described by Sherman and Fyfe (11 Proc. Natl. Acad. Sci. USA 92 (1995) where necessary, the reduction by any 2',3'-dideoxynucleoside 5'-triphosphates (ddNTPs) present in the cell extract (12) .
Nucleoside Kinase and 5'-Nucleotidase Assays. The nucleoside kinase activities were assayed essentially as described (13) . The standard nucleoside kinase reaction mixture contained 100 mM Tris HCl (pH 7.5), bovine serum albumin (0.5 mg/ml), 2 mM Mg-ATP, 3 mM phosphocreatine, 1 unit of creatine phosphokinase, 4 (16) . PCR signals obtained from the infected PBM cells were compared with PCR signals from 1:10 serial dilutions of ACH-2 cells (HIV-1 proviral DNA copies). As described (15), 3-globin sequences were amplified from the same DNA extracts to normalize the amount of DNA used.
RESULTS AND DISCUSSION
Disproportionate Inhibition and Stimulation of Deoxyribonucleoside Triphosphorylation in PBM Cells. We initially quantified the four dNTP pools at low hydroxyurea concentrations ('0.1 mM) in PHA-PBM cells. A sensitive enzymatic assay (with a minimum detection limit of 0.1 pmol) was chosen for dNTP determinations (12) . Only the dATP pool was susceptible to depletion by hydroxyurea under these conditions: a single exposure to 0.1 mM hydroxyurea caused a rapid decrease in the dATP pool of >50% (Fig. 1) . The inhibition of dATP formation by hydroxyurea was reversible and biphasic: a rapid initial decrease for -12 h, followed by a much slower recovery phase. After 48 h of continuous exposure to 0.1 mM hydroxyurea, the dATP pool still remained 20% lower than the no-drug control. In contrast, dTTP and dCTP pools continuously increased up to 3 days compared with no-drug controls. The level of dGTP also increased; this increase, however, was slower and appeared to parallel the increase of dTTP. These results suggest that although hydroxyurea increases the anti-HIV-1 potencies of all three dideoxynucleosides-AZT, ddCyd, and ddlno-only ddlno potency can be increased through the mechanism of inhibition of synthesis of its competing deoxynucleotide, dATP, in PBM cells. Since the reversible inhibition of dATP pool size by hydroxyurea in the absence of ddlno exerted only minor inhibition ('10%) of viral replication (5) and since the increases of dTTP and dCTP would, barring other factors, decrease rather than increase the anti-HIV potencies of AZT and ddCyd, respectively, it follows that the enhancement of AZT and ddCyd activities by low- dose hydroxyurea must be through a mechanism other than direct inhibition of the generation of physiological deoxynucleosides by ribonucleotide reductase.
Selective Enhancement ofAnabolic Phosphorylation ofAZT and ddCyd. The paradoxical increases of dTTP and dCTP pools in PHA-PBM cells by hydroxyurea imply that in the case of these two deoxynucleotides, an increase in salvage synthesis predominates over the inhibition of ribonucleotide reductase by hydroxyurea. Since anabolic phosphorylation of AZT and ddCyd shares the same pathways as those for dThd and dCyd, respectively, we evaluated the effect of hydroxyurea on the phosphorylation of AZT and ddCyd in PHA-PBM cells and compared it with that of ddlno. In our earlier studies (10), AZT was found to be more rapidly phosphorylated than ddCyd and ddlno, with the largest amounts of AZT phosphates being formed at 12 h. This time period was thus chosen for comparison of hydroxyurea effects on phosphorylation. As shown in Table 1 , the exposure of PBM cells to 3H-labeled AZT, ddCyd, and ddIno resulted in increases of intracellular AZTTP and ddCTP, which correlated with increases in hy-8334 Pharmacology: Gao et al. droxyurea concentration. In marked contrast, there was no increase of ddATP, the active metabolite of ddlno, as hydroxyurea concentration increased (Table 1) . Furthermore, among all three AZT metabolites examined, AZT monophosphate (AZTMP) was the most rapidly increased by hydroxyurea ( Table 2 ), indicating that hydroxyurea primarily targets the conversion of AZT to AZTMP by thymidine kinase. This is consistent with the earlier report by Karlsson et al. (9) using a human lymphoblastoid cell line (CEM) (9) . For ddCyd, the enhancement effect of hydroxyurea on deoxycytidine kinase (Fig. 2) , while dose-dependent, was less striking because of the low affinity and low reaction velocity of ddCyd as a substrate for this enzyme (17) , although the total phosphorylated forms of ddCyd increased by 19.2% (Table 1) ; among these phosphorylated forms are the longlived phosphodiesters of ddCyd, ddCDP choline (where ddCDP is 2',3'-dideoxycytidine 5'-diphosphate), and ddCDP ethanolamine, which may act as slow-release or "depot" forms of ddCTP (18) . Since, in human cells, nucleotide diphosphate kinases are in excess compared to nucleoside kinases and nucleotide monophosphate kinases (19) , the sum of the total metabolite pools in Table 2 represents the phosphorylation efficiency of thymidine kinase and deoxycytidine kinase, respectively, whereas the sum of di-and triphosphates (and, for ddCyd, the ddCDP diesters as well) represent primarily the activity of dTMP kinase and dCMP kinase.
On the other hand, while the anabolic phosphorylation of ddIno actually decreased slightly (3%), the ratio of ddATP/ dATP, nevertheless, increased by 2.3-fold in the presence of 0.1 mM hydroxyurea because of the substantial decrease (58%) of the dATP pool in contrast to the increases in the dTTP and dCTP pools ( Table 1) . As a consequence, at 12 h (when the maximal AZT/dTTP ratio was obtained), the increase of the ddATP/dATP ratio was substantially higher than the increases in the ratios of AZTTP/dTTP or ddCTP/ dCTP. This result provides an explanation as to why the hydroxyurea/ddlno combination shows more effective anti-HIV-1 activity than do the combinations of hydroxyurea/AZT and hydroxyurea/ddCyd (5, 7)-i.e., because the ddNTP/ dNTP ratio is of greater pharmacological importance for ddN anti-HIV activity than is the absolute ddNTP value. However, the increases by hydroxyurea of the intracellular pyrimidine ddNTPs, AZTTP and ddCTP, are of importance in the potentiation of the antiviral activities of AZT and ddCyd, because AZTTP and ddCTP have higher affinities for HIV-1 reverse transcriptase than do their respective physiological dNTPs, dTTP and dCTP (20) . The expanded pool sizes of the long-lasting phosphodiester metabolites of ddCyd (ddCDP choline and ddCDP ethanolamine, Table 2 ) may also contribute to the overall increases of the anti-HIV-1 activity of ddCyd (5) .
Effects of Hydroxyurea on Cellular Kinases and 5'-Nucleotidase. We then evaluated the effect of hydroxyurea on cellular nucleoside kinases catalyzing the initial step (rate limiting step) of the salvage synthesis of dNTPs (21) , in comparison with the enzymes responsible for de novo synthesis. The effect of hydroxyurea on the cytosolic 5'-nucleotidase (phosphotransferase) responsible for catalysis of the first step of ddIno phosphorylation was also determined. Although hydroxyurea is an inhibitor of ribonucleotide reductase, it also increased the activities of pyrimidine deoxynucleoside kinases in a dose-and time-dependent manner (Fig. 2) ; this effect of hydroxyurea did not extend, however, to the kinases in the de novo' pathway such as uridine-cytidine kinase ( Fig. 2A and B) and adenosine kinase (unpublished data). Similarly, hydroxyurea was also found to have no enhancement effect on the cytosolic 5'-nucleotidase (phosphotransferase) responsible for ddlno phosphorylation (data not shown). Thus, the potentiation of AZT, ddCyd, and ddIno activities by hydroxyurea involves at least two mechanisms, as depicted schematically in (A and B) Concentration effects of hydroxyurea on ribonucleoside kinases. Activated PI3M cells were exposed to hydroxyurea at indicated concentrations for 24 h. All enzyme assays were performed at 37°C as described (10) . The reaction mixtures for determination of thymidine kinase (TK), deoxycytidine kinase (dCK), cytidine kinase (CK), and uridine kinase (UK) contained 0.1 mM 14C-labeled thymidine, deoxycytidine, cytidine, and uridine, respectively. Data represent the means of percent enzyme activity compared with no-drug control (from PBM-cell preparations from three donors). (C and D) Time-dependent activation of thymidine kinase and deoxycytidine kinase activities by hydroxyurea. Activated PBM cells were exposed to 0.05 mM hydroxyurea (HU). At the indicated time, cells were harvested and intracellular pyrimidine deoxyribonucleoside kinase activities were assayed. Data represent the mean of the kinase activities determined in duplicate from PBM-cell preparations from two donors. Fig. 3 . Anti-HIV-1 activities of AZT and ddCyd are potentiated through the hydroxyurea-induced increases of phosphorylation of AZT and ddC by increased thymidine kinase and deoxycytidine kinase activities, respectively. These effects of hydroxyurea directly increase the drug (AZTTP or ddCTP) pressure on HIV-1 reverse transcription but also cause countervailing increases of dTTP and dCTP synthesis (Fig. 1) . In marked contrast, hydroxyurea increases ddlno activity through inhibition of host dATP synthesis (Fig. 1) . Thus, the ddlno/ hydroxyurea combination, unlike the AZT/hydroxyurea or ddCyd/hydroxyurea combinations, is able to target both a prereplicational step (dATP formation) and the reverse transcription step.
The mechanism responsible for the increases of thymidine kinase and deoxycytidine kinase activities by hydroxyurea is not entirely clear. Our enzyme studies show that this compound (0.02-100 mM) does not exert any detectable direct stimulative effects on the activity of these kinases (data not shown). Since human cytosolic thymidine kinase is a cell-cycle- regulated enzyme with the highest activity in S phase (22) , while deoxycytidine kinase activity is also increased in S phase in certain cell types (23) (Fig. 1) . This result suggests that the dATP'pool in PBM cells is primarily formed through the de novo pathway and that when this process is inhibited by hydroxyurea, the salvage synthesis of dATP is inefficient compared with dTTP and dCTP synthesis. The increase of dGTP could be a secondary consequence of the dTTP increase, since dTTP is an essential allosteric activator for GDP reduction by ribonucleotide reductase (25) ; alternatively, the increase in deoxycytidine kinase seen in hydroxyurea-treated PHA-PBM cells could be responsible for the increase via the salvage pathway, because deoxyguanosine is known to be an alternate substrate for this enzyme (26 (1 ,uM) did not exhibit appreciable inhibitory activity (Fig. 4) , suggesting that ddlno has less activity in activated than in resting cells due to the high levels of dATP in the former (10) . However, PCR analysis shows that ddlno potency was profoundly increased in the presence of hydroxyurea (Fig. 4) (14) ] to compete with dATP and thus effectively terminates viral DNA synthesis.
In summary, hydroxyurea in combination with ddIno has been shown to target HIV-1 dependency on host dATP synthesis. However, the hydroxyurea stimulation effect on the salvage synthesis of dTTP and dCTP, likely through partial PHA-PBM cell synchronization in early S phase, indicates that AZT/hydroxyurea and ddCyd/hydroxyurea combinations do not act by this mechanism (depletion of dNTPs) in limiting HIV-1 replication. For this reason, in the design of potential combinations of ribonucleotide reductase inhibitors and ddNs, the conditions should be carefully defined: (i) host dNTP pools should be observed and quantified under the same conditions in which the antiviral activity was defined, (ii) the impact of the ribonucleotide reductase inhibitor on nucleoside kinases in the salvage synthesis of dNTPs should be examined, and (iii) the response of the phosphorylation of ddNs to the ribonucleotide reductase inhibitor should be evaluated. Our study shows that only when ddATP-generating agents (such as the inosinebased and adenosine-based dideoxynucleosides, ddIno and ddAdo) are combined with hydroxyurea are the prereplicational event (dATP synthesis) and the replicational event (viral reverse transcription) simultaneously targeted. These findings explain why these purine-based ddN/hydroxyurea combinations have more effective anti-HIV-1 activity than hydroxyurea combined with pyrimidine-based dideoxynucleosides such as AZT and ddCyd.
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